The RpoB H148Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in staphylococcus aureus

Journal of Infectious Diseases

Volumn 207, Issue 6, 2013, Pages 929-939

  Gao, Wei ^a,b,d   Cameron, David R ^d   Davies, John K ^d   Kostoulias, Xenia ^d   Stepnell, Justin ^b   Tuck, Kellie L ^e   Yeaman, Michael R ^f,g   Peleg, Anton Y ^c,d,h   Stinear, Timothy P ^b,d   Howden, Benjamin P ^a,b,d  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d Department of Microbiology ^*  (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UCLA MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

antibiotic resistance; persistence; Staphylococcus aureus; virulence

Indexed keywords

DAPTOMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; TRANSCRIPTION FACTOR RELA; VANCOMYCIN; ALPHA DEFENSIN; BETA DEFENSIN; DEFB4A PROTEIN, HUMAN; DEFENSIN 1; DNA DIRECTED RNA POLYMERASE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA SEQUENCE; FEMALE; GENETIC MANIPULATION; HOST PATHOGEN INTERACTION; INNATE IMMUNITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; UPREGULATION; WILD TYPE; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL CAPSULE; BAGG ALBINO MOUSE; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCUS INFECTION; VIRULENCE;

ALPHA-DEFENSINS; ANIMALS; BACTERIAL CAPSULES; BETA-DEFENSINS; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; UP-REGULATION; VIRULENCE;

MLCS; MLOWN;

EID: 84874224139     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis772     Document Type: Article

References (49)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32.
2. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521-8.
3. Peleg AY, Miyakis S, Ward DV, et al. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 2012; 7:e28316.
4. Watanabe Y, Cui L, Katayama Y, Kozue K, Hiramatsu K. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J Clin Microbiol 2011; 49:2680-4.
5. Cameron DR, Ward DV, Kostoulias X, et al. Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. J Infect Dis 2012; 205:1677-87.
6. Moise PA, Forrest A, Bayer AS, Xiong YQ, Yeaman MR, Sakoulas G. Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes. J Infect Dis 2010; 201:233-40.
7. Tuchscherr L, Medina E, Hussain M, et al. Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol Med 2011; 3:129-41.
8. Fowler VG Jr., Sakoulas G, McIntyre LM, et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombininduced platelet microbicidal protein. J Infect Dis 2004; 190:1140-9.
9. Xiong YQ, Fowler VG, Yeaman MR, Perdreau-Remington F, Kreiswirth BN, Bayer AS. Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J Infect Dis 2009; 199:201-8.
10. Proctor RA, von Eiff C, Kahl BC, et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4:295-305.
11. Tenover FC, Sinner SW, Segal RE, et al. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int J Antimicrob Agents 2009; 33:564-8.
12. Mwangi MM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 104:9451-6.
13. Mariani PG, Sader HS, Jones RN. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother 2006; 58:481-3.
14. Howden BP, McEvoy CR, Allen DL, et al. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 2011; 7: e1002359.
15. Gao W, Chua K, Davies JK, et al. Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog 2010; 6:e1000944.
16. Dalebroux ZD, Svensson SL, Gaynor EC, Swanson MS. ppGpp conjures bacterial virulence. Microbiol Mol Biol Rev 2010; 74:171-99.
17. Aubry-Damon H, Soussy CJ, Courvalin P. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1998; 42:2590-4.
18. O'Neill AJ, Huovinen T, Fishwick CW, Chopra I. Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob Agents Chemother 2006; 50: 298-309.
19. Garzoni C, Kelley WL. Return of the Trojan horse: intracellular phenotype switching and immune evasion by Staphylococcus aureus. EMBO Mol Med 2011; 3:115-7.
20. Mishra NN, McKinnell J, Yeaman MR, et al. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55:4012-8.
21. Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G. Reduced susceptibility to host defense cationic peptides and daptomycin coemerge in MRSA from daptomycin-naive bacteremic patients. J Infect Dis 2012; 206:1160-7.
22. Bae T, Schneewind O. Allelic replacement in Staphylococcus aureus with inducible counter-selection. Plasmid 2006; 55:58-63.
23. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:Article3.
24. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 2002; 3:SOFTWARE0003.
25. Liu GY, Essex A, Buchanan JT, et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med 2005; 202:209-15.
26. Yount NY, Yeaman MR. Multidimensional signatures in antimicrobial peptides. Proc Natl Acad Sci USA 2004; 101:7363-8.
27. Yount NY, Kupferwasser D, Spisni A, et al. Selective reciprocity in antimicrobial activity versus cytotoxicity of hBD-2 and crotamine. Proc Natl Acad Sci USA 2009; 106:14972-7.
28. Voyich JM, Braughton KR, Sturdevant DE, et al. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol 2005; 175:3907-19.
29. Thakker M, Park JS, Carey V, Lee JC. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun 1998; 66:5183-9.
30. Nizet V. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr Issues Mol Biol 2006; 8:11-26.
31. Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol 1988; 202:45-58.
32. Malshetty V, Kurthkoti K, China A, et al. Novel insertion and deletion mutants of RpoB that render Mycobacterium smegmatis RNA polymerase resistant to rifampicin-mediated inhibition of transcription. Microbiology 2010; 156(Pt 5):1565-73.
33. Jansen van Rensburg MJ, Whitelaw AC, Elisha BG. Genetic basis of rifampicin resistance in methicillin-resistant Staphylococcus aureus suggests clonal expansion in hospitals in Cape Town, South Africa. BMC Microbiol 2012; 12:46.
34. Yu J, Wu J, Francis KP, Purchio TF, Kadurugamuwa JL. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother 2005; 55:528-34.
35. Wichelhaus TA, Boddinghaus B, Besier S, Schafer V, Brade V, Ludwig A. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:3381-5.
36. Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu K. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISAto-VISA phenotypic conversion of strain Mu3. Antimicrob Agents Chemother 2011; 55:4188-95.
37. Nilsson IM, Lee JC, Bremell T, Rydén C, Tarkowski A. The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect Immun 1997; 65:4216-21.
38. Luong TT, Lee CY. Overproduction of type 8 capsular polysaccharide augments Staphylococcus aureus virulence. Infect Immun 2002; 70:3389-95.
39. Kampen AH, Tollersrud T, Lund A. Staphylococcus aureus capsular polysaccharide types 5 and 8 reduce killing by bovine neutrophils in vitro. Infect Immun 2005; 73:1578-83.
40. Shiro H, Muller E, Gutierrez N, et al. Transposon mutants of Staphylococcus epidermidis deficient in elaboration of capsular polysaccharide/adhesin and slime are avirulent in a rabbit model of endocarditis. J Infect Dis 1994; 169:1042-9.
41. Queck SY, Jameson-Lee M, Villaruz AE, et al. RNAIII-independent target gene control by the agr quorum-sensing system: insight into the evolution of virulence regulation in Staphylococcus aureus. Mol Cell 2008; 32:150-8.
42. Surewaard BG, Nijland R, Spaan AN, Kruijtzer JA, de Haas CJ, van Strijp JA. Inactivation of staphylococcal phenol soluble modulins by serum lipoprotein particles. PLoS Pathog 2012; 8:e1002606.
43. Xiong YQ, Mukhopadhyay K, Yeaman MR, Adler-Moore J, Bayer AS. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:3114-21.
44. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Gotz F. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 1999; 274:8405-10.
45. Peschel A, Jack RW, Otto M, et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 2001; 193:1067-76.
46. Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Bengoechea JA. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun 2004; 72:7107-14.
47. Llobet E, Tomás JM, Bengoechea JA. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology 2008; 154(Pt 12): 3877-86.
48. Campos MA, Vargas MA, Regueiro V, Llompart CM, Albertí S, Bengoechea JA. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun 2004; 72:7107-14.
49. Kreiswirth BN, Lofdahl S, Betley MJ, et al. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 1983; 305:709-12.